J&J Announces Collaboration With Stop TB Partnership To Improve Access To TB Drug

Media sources report on efforts by Johnson & Johnson to improve access to Sirturo, its medication for drug-resistant tuberculosis (TB).

Bloomberg News: J&J Eases Access for Tuberculosis Drug in Poor Nations
“Johnson & Johnson is taking steps to ensure Sirturo, its medicine for people with drug-resistant tuberculosis, is available and properly administered in 130 developing countries across the globe…” (Cortez, 4/29).

Johnson & Johnson: Johnson & Johnson Announces New Collaboration with Stop TB Partnership’s Global Drug Facility to Enhance Access to Anti-TB Compound
“Johnson & Johnson [Tuesday] announced that its affiliate Janssen Pharmaceutica NV (Janssen) has entered into a novel collaboration with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF), to facilitate access to the company’s anti-tuberculosis medicine. This public-private partnership was established by the newly formed Janssen Global Public Health and is the latest in the company’s overall efforts to improve public health…” (4/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.